This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apple's iWatch May Need FDA Approval -- and That's a Good Thing

Stocks in this article: AAPL SSNLF GOOG SNE

NEW YORK (TheStreet) -- Not a day goes by where there isn't another iWatch rumor. Investors and customers alike are eagerly awaiting the iWatch. So why is Apple taking so long to release its iWatch?

We've heard the term "time is money." For Apple (AAPL), time may be worth upwards of $50 billion in the first few years of iWatch sales.

Both Reuters and the Wall Street Journal believe Apple can sell between 50 and 60 million units. According to these reports, the iWatch, which is expected to come in various sizes, may be priced in a range from $300 to as high at $1,000.

Eva Dou and Lorraine Luk of the WSJ explain:

"Apple aims to address an overarching criticism of existing smartwatches that they don't provide functions significantly different from that of a smartphone."

Dou and Luk are referring to (among others) Samsung's (SSNLF) Gear line of smartwatches. Samsung has sold roughly 2 million of the devices last year. Of that total, 1.2 million were based on the Google's (GOOG) Android operating system. Other smartwatch makers include Sony (SNE) and Pebble.

The market is just beginning to bloom, however. According to the research firm IDC, the wearable industry will explode to 112 million devices in the next four years -- even though only 6 million units were sold in 2013. That's an annual growth rate of 450% over the next four years. 

But wearables have been a tough nut to crack.

Apple CEO Tim Cook once said that for Apple to disrupt the wearable market, the product has to be a "must-have" and not merely a "want." And this is why, according to Apple Toolbox, Apple has met with the Food and Drug Administration to asses the iWatch's "must-have" capabilities.

To separate the iWatch from the rest of the crowd, Apple is focusing not just on the device's electronic and technical capabilities. Apple wants the iWatch to emerge as an actual medical and health device.

To that end, Apple's announcement about its HealthKit at its Worldwide Developer Conference earlier this month hinted at the iWatch's potential health-monitoring sensors. It will will allow wearers to track oxygen saturation, calorie consumption, weight and sleep activity among other metrics.

Reports also suggest that the iWatch may offer a non-invasive way to check blood-sugar levels with the use of a glucometer. In other words, the device may be able to tell a wearer his or her glucose level without a needle or drawing blood. And that's where Apple's ambitions cross the jurisdiction of the FDA.

That's huge.

Under the Freedom of Information Act, Apple Toolbox requested and received a response from the FDA, which affirms that Apple officials met with the FDA last December to discuss mobile health.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs